Method of treating multiple sclerosis with interferon-beta and an IL-2R antagonist

US8298525B2 · kind B2 · utility

Assignee

• The United States of America as Represented by the Secretary of the Department of Health and Human Services · US

Inventors

• Roland Martin · Hamburg, DE
• Henry McFarland · Gaithersburg, US
• Bibiana Bielekova · Kensington, US
• Thomas Waldmann · Silver Spring, US

Key dates

• Filing date: Mar 10, 2009
• Grant date: Oct 30, 2012
• Expiry date: Mar 20, 2030

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/76
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Disclosed is a method of administering an interleukin-2 receptor (IL-2R) antagonist to a subject to treat an autoimmune disease. In particular embodiments, the IL-2R antagonist is an anti-IL-2R monoclonal antibody specific for one or more chains of the IL-2R, such as the alpha-chain, for example daclizumab. In other particular embodiments the autoimmune disease is multiple sclerosis. In certain embodiments administration of interferon-beta is combined with administration of an antagonist of the IL-2R to provide significant clinical improvement in a subject with an autoimmune disease.